By 2030, the cell and gene therapy market is projected to be worth £76.03bn, and logistics is essential in realising the ...

US President Donald Trump’s One Big Beautiful Bill Act (H.R. 1) has narrowly passed after US Vice President JD Vance broke a 50-50 deadlock in the US Senate.

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis portfolio.

Jazz Pharmaceuticals has received conditional marketing authorisation from the European Commission for Ziihera for biliary tract cancer.

Sanofi is to invest up to $25m in Adagene, which will enable the latter to fund its R&D efforts, including clinical development of muzastotug.

Uruguay’s MSP has tasked a working group and a proposal has been created by the Faculty of Chemistry at the University of Uruguay.

Proposals for drug exclusivities and feeble measures to combat drug shortages are unlikely to boost innovation, say some ...

Sanofi's antibody riliprubart has received orphan drug designation from Japan's MHLW for its potential to treat CIDP.

The sale caps a difficult time for zilovertamab and ONCT-808 under Oncternal’s ownership. Zilovertamab was deprioritised by ...

Piramal Pharma invests $90m to expand its two US facilities, enhancing manufacturing capabilities for sterile injectables and ...